Bayer's Phase II Trial of BAY3283142 Aims to Treat Chronic Kidney Disease
Key Insights
Bayer has initiated the ALPINE-1 Phase II clinical trial to evaluate BAY3283142, a soluble guanylate cyclase (search) (sGC) activator, for treating chronic kidney disease (search) (CKD).
The ALPINE-1 study is a randomized, double-blind, placebo-controlled, multi-center trial assessing the efficacy and safety of BAY3283142 in CKD patients.
BAY3283142 modulates the nitric oxide (NO)-soluble guanylate cyclase (search) (sGC)-cyclic guanosine monophosphate (cGMP) pathway, showing potential in cardiovascular diseases.
Bayer has commenced the ALPINE-1 Phase II clinical trial to investigate BAY3283142, an investigational soluble guanylate cyclase (search) (sGC) activator, for the treatment of chronic kidney disease (search) (CKD). The study aims to evaluate the efficacy and safety of BAY3283142 in patients with CKD, a condition affecting approximately 850 million people worldwide.
The ALPINE-1 trial is designed as a randomized, double-blind, placebo-controlled, multi-center study. Following successful first-in-human trials, this Phase II trial will further assess the potential of BAY3283142 in modulating the nitric oxide (NO)-soluble guanylate cyclase (search) (sGC)-cyclic guanosine monophosphate (cGMP) pathway.
Unmet Needs in CKD Treatment
CKD is a progressive condition often linked with diabetes and cardiovascular disease (search). It remains widely underrecognized, with many symptoms not appearing until the disease is advanced. The prevalence of CKD underscores the urgent need for effective treatment options.
"This study marks a significant step forward in our commitment to addressing the high unmet medical need in this patient population and advancing our innovative approach to treat renal disease," said Dr. Christian Rommel, Head of Research and Development at Bayer’s Pharmaceuticals Division.
BAY3283142: A Novel sGC Activator
BAY3283142 represents an innovative approach to treating cardiovascular diseases by activating soluble guanylate cyclase (search) (sGC). The drug aims to improve outcomes for patients with chronic kidney disease (search) and related cardiovascular conditions.
Expert Perspectives
Prof. Christoph Wanner, Senior Professor of Medicine at the University Hospital of Würzburg and Co-Chair of the ALPINE-1 study, emphasized the importance of addressing CKD, noting that its prevalence as a leading cause of mortality necessitates effective treatment options. "The evaluation of the sGC activator in patients with CKD holds promise in addressing a critical unmet medical need in patient care," he stated.
Bayer's Commitment
Bayer is dedicated to advancing treatments for cardiovascular and kidney diseases. The company focuses on targets and pathways with the potential to significantly impact how these diseases are treated, reflecting their commitment to innovation in healthcare.